Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02386917
NCT02386917Active, not recruitingNot Applicable

Impact of Body Weight, Low Calorie Diet and Gastric Bypass on Drug Bioavailability, Cardiovascular Risk Factors and Metabolic Biomarkers

The Hospital of Vestfold2 sites in 1 country100 target enrollmentStarted: March 18, 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
100
Locations
2
Primary Endpoint
Bioavailability of drugs (1)
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Drug bioavailability and disposition vary according to body weight and weight loss after bariatric surgery. This study evaluates the impact of body weight and weight loss on the pharmacokinetics of various probe drugs, and compares these effects in three groups of patients receiving either a gall bladder operation, gastric bypass or a very low calorie diet.

Detailed Description

This study aims to

  1. to investigate the relationship between body composition and the liver/intestine activity and expression of proteins (drug metabolizing enzymes, transporters and regulatory factors) important for drug bioavailability and disposition in the range from normal to morbid obesity (the combined gastric bypass and cholecystectomy groups) at baseline.
  2. to compare the short-term (6-week) and long-term (2 years) effect of gastric bypass (GBP) and a very low calorie diet (VLCD) (matched weight loss) on bioavailability and pharmacokinetics of probe drugs (caffeine, omeprazole, digoxin, midazolam, rosuvastatin, losartan) and biomarkers (and adjoining protein expressions) for cytochrome P450 (CYP)1A2, CYP2C9, CYP2C19, CYP3A, P-glycoprotein (gp) and organic anion-transporting polypeptide (OATP)1B1.
  3. to compare the 3 study groups (GBP, VLCD and cholecystectomy) at baseline with respect to body composition, cardiovascular risk factors and metabolic biomarkers.
  4. to compare the short-term (6-week) changes in glucose metabolism, blood pressure, blood lipids and body composition of matched weight loss and long-term effects (2 year) on body composition, cardiovascular risk factors and metabolic biomarkers, between the GBP and VLCD groups.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Basic Science
Masking
Single (Investigator)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients scheduled for GBP surgery or VLCD intervention for obesity as well as patients scheduled for cholecystectomy.
  • •BMI ≥ 18.5 kg/m2
  • •Able and willing to donate biopsies (as specified in the protocol) and for the GBP and VLCD patients also willing to perform follow-up 24 hour PK-investigations and other assessments as required by the clinical study protocol
  • •Stable body weight (< 5 kg self reported weight change) during the last 3 months before inclusion.
  • •Signed informed consent.

Exclusion Criteria

  • •Concomitant treatment with drugs (according to available literature, appendix 3) and/or other factors that may influence the cocktail drug pharmacokinetics such as grapefruit juice, Seville oranges, Pomelo juice, St. Johns wort, tobacco and coffee/tea in close approximation to the investigations.
  • •Bradyarrhythmia, Wolff-Parkinson-White (WPW)-syndrome, atrioventricular block 2-
  • •Electrolyte disturbances (particularly hypokalemia or hypomagnesemia).
  • •Renal impairment: eGFR < 30 mL/min.
  • •Blood donations the last 4 months.
  • •Previous bariatric or upper gastrointestinal surgery.
  • •Diabetic patients treated with glitazones, insulin or sulfonylureas.
  • •Pregnancy (checked with HCG in urine at screening) and breast-feeding mothers.
  • •Known hypersensitivity (including allergy) to drugs included in the cocktail and/or local anesthesia.
  • •Anticoagulants with associated risk in combination with biopsies.
  • •Non-compliance with regards to visits and/or diet.

Outcomes

Primary Outcomes

Bioavailability of drugs (1)

Time Frame: 0 hours and 0.25, 0.5, 1, 1.5, 2, 3, 4, 4.25, 4.5, 5, 5.5, 6, 8, 10*, 12*, 23 and 24 hours following administration

Changes in absolute bioavailability (Area Under Curve - oral / Area Under Curve -intravenous) of midazolam after Gastric Bypass and Very Low Calorie Diet, respectively.

Bioavailability of drugs (2)

Time Frame: 0 hours and 0.25, 0.5, 1, 1.5, 2, 3, 4, 4.25, 4.5, 5, 5.5, 6, 8, 10*, 12*, 23 and 24 hours following administration

Changes in bioavailability (Area Under Curve - oral) of caffeine, losartan, digoxin, rosuvastatin and omeprazole after Gastric Bypass and Very Low Calorie Diet, respectively.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
The Hospital of Vestfold
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jøran Hjelmesæth

Professor, Head

The Hospital of Vestfold

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 4
Investigations on the Influence of Bariatric Surgery on the Metabolism and Absorption of AtorvastatinMorbid Obesity
NCT00331565University of Oslo School of Pharmacy36
Unknown
Not Applicable
Local GIT Hormones After Bariatric ManeuversMorbid Obesity
NCT04414072Minia University150
Recruiting
Not Applicable
Effect of BMI and body fat percentage on pharmacokinetics and analgesic effect of fentanyl after trasndermal fentanyl patch administratiocancer-related pain
JPRN-UMIN000009346Kanazawa University Hospital50
Not yet recruiting
Not Applicable
The pleiotropic metabolic effects of bariatric surgeryobesitas/hypertensie/glucose en lipiden metabolismemetabolic syndrome
NL-OMON33590Academisch Medisch Centrum30
Completed
Not Applicable
Taste Perception Pre and Post Bariatric SurgeryMorbid Obesity
NCT01536197Washington University School of Medicine33